| dc.creator |
Ugan, Yunus |
|
| dc.creator |
ŞENEL, SONER |
|
| dc.creator |
Kisacik, Bunyamin |
|
| dc.creator |
KAŞİFOĞLU, TİMUÇİN |
|
| dc.creator |
Tunc, Ercan |
|
| dc.creator |
Cobankara, Veli |
|
| dc.date |
2011-10-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:29:48Z |
|
| dc.date.available |
2021-12-03T11:29:48Z |
|
| dc.identifier |
66110ec7-42eb-4505-a97d-b6a6330c8165 |
|
| dc.identifier |
10.1007/s10067-011-1782-6 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/66110ec7-42eb-4505-a97d-b6a6330c8165/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/92284 |
|
| dc.description |
We aimed to evaluate the efficacy and safety of long-term use of etanercept therapy in patients with spondyloarthropathy (SpA) and rheumatoid arthritis (RA) on hemodialysis (HD). Selected RA or SpA patients treated with etanercept under HD were retrospectively evaluated. Etanercept-related adverse events were closely recorded for all patients. At the follow-up, erythrocyte sedimentation rate and C-reactive protein levels were monitored. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for SpA patients and Disease Activity Score (DAS28) for RA patients were measured at every 3 or 6 months. In total five end-stage renal disease (ESRD) patients were enrolled to the study. The causes of ESRD in the study subjects were amyloidosis (n=2), analgesic nephropathy (n=2), and nephrolithiasis (n=1). Three were diagnosed as SpA and two were RA. All patients used etanercept. The median age was 39 years (range 22-72 years). The median disease duration was 12 years (range 2-20 years). The median follow-up after etanercept therapy was 18 months (range 5-33 months). DAS28 score decreased after the treatment and did not increase during follow-up in RA patients. BASDAI score decreased after the treatment during follow-up in three patients with SpA. At the follow-up, only one patient was diagnosed with septic arthritis. As a result of our study, etanercept treatment in RA and SpA patients on HD seems to be safe, well tolerated, and effective in most of the patients. Above all, due to impaired host defense in patients with ESRD, enhanced risk of infections should be kept in mind during follow-up period and larger trials are needed to prove the safety of etanercept in HD patients. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis |
|
| dc.type |
info:eu-repo/semantics/article |
|